Nanotechnology as a tool to overcome immune suppression in solid tumors

Описание: This is the talk by Prof. Helena F. Florindo (University of Lisbon, Portugal) under the interdisciplinary seminar series "Molecular Communication Outside the Box: Breaking Disciplinary Boundaries" of IEEE ComSoc's Technical Committee on MBMC.

Abstract: Among immunotherapeutic approaches, immune checkpoint inhibitors (ICI), have revolutionized the treatment of several cancers. However, limited efficacy has been obtained for cancer vaccines and severe immune-mediated side effects have been related to ICI under clinical development [1]. Looking into solid tumors, such as breast cancers and melanoma, the highly immunosuppressive tumor microenvironment (TME), and the immune evasion mechanisms have limited the infiltration by immune cells and therapeutics [2]. Here we show the synergistic therapeutic effect of nanomedicines [3] in combination with ICI in preclinical models of breast carcinoma (BC) and melanoma. Polymeric nanoparticles (NP) were designed to target dendritic cells (DC) and the TME by incorporating tumor-associated antigens, toll-like receptor ligands CpG and Poly(I:C), and regulators of potent immune suppressor molecules within the TME. NP surface was modified to promote DC activation, but also to potentiate their delivery to the TME. Cy5.5-labeled NP were extensively internalized by DC and triggered their activation in vivo. Higher levels of DC-related co-stimulatory molecules such as CD80, CD86, and CD40, were observed when compared with non-carbohydrate carriers. The anti-tumor immune-mediated effect was evaluated in vivo in melanoma/BC-bearing mouse models. NP successfully induced a potent immune-mediated anti-tumor response against melanoma and BC. Synergistic anti-tumor effects were observed when NP was combined with ICI. The multifunctional nanomedicines re-shaped the immune profiling within the TME of melanoma and BC, which correlated with the overall anti-tumor effect obtained in this combinatorial scheme. 4T1 and E0771 tumor-bearing animals treated with the multifunctional nanomedicine combined with αOX40 showed a noteworthy tumor remission, with prolonged overall survival. In conclusion, the developed nanotechnology-based system induced a strong antigen-specific immune response and unlocked melanoma and BC to standard immunotherapeutic approaches, as immune checkpoint modulators.
References
1. K. Hiam-Galvez K, et al. Nat Rev Cancer 2021, 21, 345.
2. M. A. Mintz, J.G. Cyster. Immunol Rev 2020, 296, 48.
3. J. Conniot et al. Nat Nanotech 2019, 2, 105.


Biography: Helena Florindo graduated in Pharmaceutical Sciences in 2003 (University of Lisbon) and obtained her Ph.D. degree in Pharmaceutical Technology in 2008 (University of Lisbon), in collaboration with the University of London. Currently, she is a Full Professor in the Department of Pharmacy, Pharmacology, and Health Technologies at the Faculty of Pharmacy, University of Lisbon. Since 2015, she has been the head of the BioNanoSciences – Drug Delivery & Immunoengineering Research Group, at the Research Institute for Medicines (iMed.ULisboa), University of Lisbon. Helena is also a member of the Portuguese Medicines Agency Evaluation Board (INFARMED) and an expert in the European Medicines Agency (EMA), thus supporting the evaluation of marketing authorization procedures for new drugs and biologics. This knowledge in regulatory sciences also guides the research within her research group, which has been motivated by the immune-oncology field toward the rational development of functionalized nanobiomaterials as novel immunotherapies for cancer treatment. It includes the characterization of the anti-tumor effects induced by the combination of nano-vaccines with nano-therapeutics designed to modulate the functions of key cells within tumor microenvironment, such as T cells, myeloid-derived cells, and tumor cells.



00:00 Intro
00:36 Clinical Development
05:40 Immuno-Oncology
12:00 Nanotechnology
23:05 Combination of Cancer Nanovaccine with aOX40/aPD-1
32:33 Cancer Immunoediting - Escape Phase - Suppressive Tumor
Immune Microenvironment (TIME)
33:37 COMBImmunotherapy: Deliver Tumor-Immune Network Modulators
& Nanovaccine
41:35 A Multifunctional Nanovaccine against Breast Cancer

Molecular Communication Outside the Box: Breaking Disciplinary Boundaries - YouTube Playlist:
   • Molecular Communication Outside the Box: B...  

IEEE ComSoc's Technical Committee on MBMC website: https://mbmc.committees.comsoc.org
IEEE ComSoc's Technical Committee on MBMC on LinkedIn:   / 14247935